Targeting oxidative stress mechanisms to treat Alzheimer's and Parkinson's disease: a critical review

dc.contributor.authorAborode, Abdullahi Tunde
dc.contributor.authorPustake, Manas
dc.contributor.authorAwuah, Wireko Andrew
dc.contributor.authorAlwerdani, Mariam
dc.contributor.authorShah, Parth
dc.contributor.authorYarlagadda, Rohan
dc.contributor.authorAhmad, Shahzaib
dc.contributor.authorCorreia, Inês F. Silva
dc.contributor.authorChandra, Ayush
dc.contributor.authorNansubug, Esther Patience
dc.contributor.authorAbdul-Rahman, Toufik
dc.contributor.authorMehta, Aashna
dc.contributor.authorAli, Omar
dc.contributor.authorAmaka, Shekinah Obinna
dc.contributor.authorZuñiga, Yves Miel H.
dc.contributor.authorShkodina, A. D.
dc.contributor.authorInya, Oko Christian
dc.contributor.authorShen, Bairong
dc.contributor.authorAlexiou, Athanasios
dc.contributor.authorШкодіна, Анастасія Дмитрівна
dc.date.accessioned2023-03-15T09:43:46Z
dc.date.available2023-03-15T09:43:46Z
dc.date.issued2022
dc.description.abstractNeurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) are becoming more frequent as the age increases. Contemporary therapies provide symptom resolution instead of targeting underlying pathological pathways. Consequently, there is considerable heterogeneity in response to treatment. Research has elucidated multiple potential of pathophysiological mechanisms contributing to neurodegenerative conditions, among which oxidative stress pathways appear to be suitable drug targets. The oxidative stress pathway has given rise to numerous novel pharmacological therapies that may provide a new avenue for neurodegenerative diseases. For example, SKQ (plastoquinone), MitoVitE, vitamin E, SOD mimic, MitoTEMPO (SOD mimetic), and bioactive molecules like curcumin and vitamin C have indeed been examined. To better understand how oxidative stress contributes to neurodegenerative diseases (such as Alzheimer’s and Parkinson’s), we analyzed the medicinal qualities of medicines that target markers in the cellular oxidative pathways. The specific pathway by which mitochondrial dysfunction causes neurodegeneration will require more investigation. An animal study should be carried out on medications that tackle cellular redox mechanisms but are not currently licensed for use in the management of neurodegenerative conditions.uk_UA
dc.identifier.citationTargeting oxidative stress mechanisms to treat alzheimer's and parkinson's disease: a critical review / A. T. Aborode, M. Pustake, W. A. Awuah [et al.] // Oxidative Medicine and Cellular Longevity. – 2022. – Article ID 7934442. doi: 10.1155/2022/7934442.uk_UA
dc.identifier.doihttps://doi.org/10.1155/2022/7934442
dc.identifier.urihttps://repository.pdmu.edu.ua/handle/123456789/20264
dc.language.isoenuk_UA
dc.publisherHindawiuk_UA
dc.subjectalzheimer’s diseaseuk_UA
dc.subjectparkinson’s diseaseuk_UA
dc.subjectoxidative Stressuk_UA
dc.subjectneurodegenerationuk_UA
dc.titleTargeting oxidative stress mechanisms to treat Alzheimer's and Parkinson's disease: a critical reviewuk_UA
dc.typeArticleuk_UA

Файли

Контейнер файлів
Зараз показуємо 1 - 1 з 1
Ескіз недоступний
Назва:
Targeting_oxidative_stress_mechanisms.pdf
Розмір:
916.14 KB
Формат:
Adobe Portable Document Format
Опис:
Ліцензійна угода
Зараз показуємо 1 - 1 з 1
Ескіз недоступний
Назва:
license.txt
Розмір:
4.3 KB
Формат:
Item-specific license agreed upon to submission
Опис: